Advaxis (ADXS) Announces Completion of First Dose-Escalation for AXAL + Durvalumab Combo in HPV-Associated Cancers
Tweet Send to a Friend
Advaxis, Inc. (Nasdaq: ADXS) announced their combination study with MedImmune, the global biologics research and development arm of AstraZeneca (NYSE ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
